Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody–Drug Conjugates
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1550-7416
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody–Drug Conjugates ; volume:24 ; number:4 ; day:10 ; month:6 ; year:2022 ; pages:1-12 ; date:7.2022
The AAPS journal / American Association of Pharmaceutical Scientists ; 24, Heft 4 (10.6.2022), 1-12, 7.2022
- Urheber
-
Liao, Kai H.
Williams, Jason H.
Palani, Santhosh
Yin, Donghua
Meng, Xu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1208/s12248-022-00717-x
- URN
-
urn:nbn:de:101:1-2022100622342320101451
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liao, Kai H.
- Williams, Jason H.
- Palani, Santhosh
- Yin, Donghua
- Meng, Xu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer